63449-37-6

Usage

InChI:InChI=1/C10H18O4S/c1-3-13-9(11)6-5-7-15-8-10(12)14-4-2/h3-8H2,1-2H3

Upstream product

• 3153-36-4 4-chloro-butyric acid ethyl ester 
• 141-52-6 sodium ethanolate 
• 623-51-8 ethyl 2-sulfanylacetate 
• 2969-81-5 Ethyl 4-bromobutyrate 

Downstream Products

• 97491-86-6 1-Ethoxycarbonyl-1-<4-nitro-phenylhydrazono>-2-thia-n-pentan-carbonsaeure-(5)-ethylester-dioxid-(2.2) 
• 58509-73-2 ethyl 3-oxothiane-2-carboxylate 
• 135369-32-3 ethyl 3-oxotetrahydro-2H-thiopyran-4-carboxylate 
• 1450790-46-1 2-(4-(trifluoromethyl)phenyl)-7,8-dihydro-3H-thiopyrano[3,2-d]pyrimidin-4(6H)-one 
• 1429638-98-1 (S)-1-cyclopropyl-3-(4-(4-(3-methylmorpholino)-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidin-2-yl)phenyl)urea 
• 87466-23-7 2,4-dichloro-7,8-dihydro-6H-thiopyrano<3,2-d>pyrimidine 
• 76943-07-2 tetrahydro-2H-thiopyran-3-amine 1,1-dioxide hydrochloride 
• 117593-38-1 3-aminothiacyclohexane 
• 1233704-64-7 N-ethyl-6-(3-oxo-3,5,6,7-tetrahydrothiopyrano[3,2-c]pyrazol-2(1H)-yl)-N-phenylpyridine-3-sulfonamide 
• 135369-52-7 10-Benzyl-7,8-dihydro-2-morpholino-9H,10H-thiopyrano<3,2-d>-1,2,4-triazolo<1,5-a>pyrimdin-5-one 
• 135369-53-8 10-Benzyl-6,7-dihydro-2-morpholino-5H,10H-thiopyrano<2,3-e>-1,2,4-triazolo<1,5-a>pyrimidin-9-one 
• 135369-55-0 10-Benzyl-7,8-dihydro-2-benzylamino-9H,10H-thiopyrano<3,2-d>-1,2,4-triazolo<1,5-a>pyrimidin-5-one 
• 135369-51-6 10-Benzyl-7,8-dihydro-2-diethylamino-9H,10H-thiopyrano<3,2-d>-1,2,4-triazolo<1,5-a>pyrimdin-5-one 
• 135369-46-9 10-Benzyl-7,8-dihydro-2-methylthio-9H,10H-thiopyrano<3,2-d>-1,2,4-triazolo<1,5-a>pyrimidin-5-one 

Relevant academic research and scientific papers

SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF

The present invention relates to compounds according to Formula (I-1) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS

The invention relates to compounds of formula (I) wherein m, o, Ra, Rb, R1 and T1 have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments

FUSED TRICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF JANUS KINASES

The invention provides novel compounds of formula (I) having the general formula (I) wherein R1, V, W, X, Y and Z are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.

The search for TCP analogues binding to the low affinity PCP receptor sites in the rat cerebellum

With the aim of obtaining selective ligands of the low affinity binding sites of [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine ([3H]TCP) in the rat cerebellum, oxygen and sulfur atoms were introduced in the TCP structure and derivatives to obtain analogues with a lowered lipophilicity. These compounds, and others already obtained, were assayed comparatively to determine their affinities for three sites labeled with [3H]TCP: one in the forebrain, the originally described PCP receptor, and two in the rat cerebellum. Lowering the lipophilicity and modifying the hetero-aromatic moiety yielded some ligands with increased affinity for the low affinity sites in the rat cerebellum and decreased affinity for the high affinity sites in the forebrain. Particularly, two compounds displaying both a high affinity and a good selectivity might be valuable tools to elucidate the pharmacology of the low affinity PCP sites labeled with [3H]TCP in the rat cerebellum.